Authors
Latest:
Chris Bond, PhD, on Allogeneic and Induced Pluripotent Stem Cell Approaches to Cell TherapyThe senior vice president of Research & Early Development at Notch Therapeutics discussed the company’s approach to overcoming the drawbacks of autologous cell therapies.
Latest:
Accelerating Therapy Discovery and Approval With AIDavid Dimmock, MBBS, the chief medical officer at Creyon Bio, discussed future applications for the company’s AI-guided discovery platform.
Latest:
Neutralizing Antibody Versus Total Antibody Assays in Gene Therapy Development: Key Considerations for Assessing ImmunogenicityViral vectors have become the most common method for delivering gene therapy; however, pre-existing humoral immunogenicity can potentially render a gene therapy ineffective.
Latest:
Juliane Gust, MD, PhD, on Evaluating Longterm Neurological Outcomes for CAR-T in Pediatric PatientsThe assistant professor of neurology at University of Washington, Seattle Children's discussed efforts to address a gap in knowledge in the long-term effects of CAR-T, if any, on children’s neurological development.
Latest:
Achieving Remission in Lupus With CAR T TherapyTeodora Staeva, PhD, chief scientific officer, Lupus Research Alliance, discussed the potential of the approach in patients with SLE.
Latest:
Weighing Benefits and Risks of Cell Therapy in Multiple Myeloma: Suzanne Lentzsch, MDThe professor of clinical medicine, director, Multiple Myeloma and Amyloidosis Program, New York-Presbyterian Hospital, discussed utility of cellular therapies in multiple myeloma.
Latest:
Tom E. Howard, MD, PhD, on a Gene Editing Approach to Treating Hemophilia AThe clinical professor in the Department of Human Genetics at University of Texas Rio Grande Valley discussed how a personalized gene editing approach may help patients avoid development of FVIII inhibitors.
Latest:
Bella Neufeld, PhD, on Addressing Pain Points in AAV Gene Therapy DevelopmentThe director of research and development at Teknova discussed the company’s recent announcement of a new line of products intended to streamline process development in AAV gene therapy manufacturing.
Latest:
Nadezhda Omelchenko, MD, on Treating Rare Sarcomas With Autologous Natural Killer Cell TherapyThe research associate at Cancer Center of Southern California in Santa Monica discussed findings from 3 patients treated with a combination therapy that included NK cell therapy SNK01.
Latest:
STRIVE-02: First-in-Human B7H3 CAR T-Cells for Pediatric Patients With Relapsed/Refractory Solid TumorsThree of the 9 patients who received the infusion demonstrated best overall response of Stable Disease, and investigators determined dose level 2 to be the biologically effective dose.
Latest:
Improving Outcomes in Corneal Endothelial Disease With Cell TherapyGreg Kunst, chief executive officer, Aurion Biotech, discussed the potential of cell therapy in treating people with corneal endothelial disease around the world.
Latest:
Alessandro Aiuti, MD, PhD, on Durable, Clinically Meaningful Efficacy of Arsa-Cel in Metachromatic LeukodystrophyThe deputy director, clinical research, San Raffaele Telethon Institute for gene therapy, discussed long-term follow-up data of up to 12 years.
Latest:
Genetic and Gender Factors Linked to Fuchs Endothelial Corneal Dystrophy in University College London StudyThese findings could support gene therapies targeting CTG18.1 that are currently in development.
Latest:
Amit Soni, MD, on Challenges to the Uptake of Gene Therapy for HemophiliaThe medical director of the Center for Inherited Blood Disorders discussed barriers to the widespread adoption of val-rox by the hemophilia A community.
Latest:
Mary Jane "MJ" Mulcahey, PhD, OTR/L, CPPC, CLCP, FASIA, on Reevaluating Outcome Measures for Spinal Cord Injury Clinical TrialsThe director of the Center for Outcomes and Measurement in the Jefferson College of Rehabilitation Sciences at Thomas Jefferson University discussed the research she presented at the first Annual SCI Investor Symposium.
Latest:
Expanding the Use of CAR T Therapy With shRNAThe chief executive and chief medical officers of Celyad Oncology discussed the company’s future research and plans.
Latest:
Potential of mRNA-Based Gene TherapiesJake Becraft, PhD, chief executive officer and cofounder, Strand Therapeutics, discussed the company’s future research and plans.
Latest:
Peter A. Merkel, MD, MPH, on the Challenges of Bringing Cell Therapy to Autoimmune DiseaseThe chief of the Division of Rheumatology and professor of medicine and professor of epidemiology at Penn Medicine discussed challenges on the horizon in this rapidly emerging field.
Latest:
Fernanda Mesquita, PhD, on Using LAMA2-Exosomes to Improve Cardiomyocyte Survival in StrokeThe research associate at the The Texas Heart Institute discussed preclinical research she presented at AHA’s 2023 Scientific Sessions on MSC-derived exosomes.
Latest:
Chiraag Kapadia on Investigating Clonal Hematopoiesis After CAR T-cell TherapyThe MD, PhD candidate at Baylor College of Medicine discussed findings from a new study presented at the 2023 Tandem Meetings.
Latest:
Mark Forman, MD, PhD, on Genetic Testing and Further Research in Frontotemporal DementiaThe chief medical officer of Passage Bio discussed research needs in FTD.
Latest:
WVU Cancer Institute Cellular Therapy Program Recognized by the Foundation for the Accreditation of Cellular TherapyLauren Veltri, MD Director, WVU Cancer Institute Hematopoietic Malignancy and Cellular Therapy Program, discussed the recent FACT accreditation.
Latest:
Eileen Tzng, BA, on Exploring Exosome and RNA-based Treatment Methods for Heart FailureThe life science research professional at Stanford University discussed preclinical research she presented at the American Heart Association’s Scientific Sessions 2023.
Latest:
James Gulley, MD, PhD, FACP, on Assessing a Novel TCR Bifunctional Antibody in CPI-Resistant Solid TumorsThe director of the Medical Oncology Service at the National Cancer Institute discussed the START-001 trial.
Latest:
CGTLive®’s Weekly Rewind – March 21, 2025Review top news and interview highlights from the week ending March 21, 2025.
Latest:
Deborah Phippard, PhD, on the Challenges of Evaluating Gene Therapy for Parkinson DiseaseThe chief scientific officer of Precision for Medicine discussed unique difficulties of designing clinical trials for PD gene therapy candidates.
Latest:
Performing In-Depth Analysis of Lentiviral Cell Therapies: Luca Biasco, PhDThe director of research and development at AVROBIO discussed the molecular follow-up of cell therapies.
Latest:
Caribou Biosciences' chRDNA Technology May Enable New Treatments for ATTR and Familial HypercholesterolemiaSteve Kanner, PhD, the chief scientific officer of Caribou Biosciences, discussed results from preclinical research evaluating the gene editing approach.
Latest:
Paul Wuh-Liang Hwu, MD, PhD, on Questions Remaining With AADC DeficiencyUpstaza has been granted marketing authorization by the European Commission.
Latest:
CARTITUDE Trials in Multiple MyelomaExperts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.
